Exact Sciences

EXAS

Last Price
03/23/26, 09:30 AM
 EDT
$
104.91
(
0.0
%)
(
+
0.0
%)
Margin of Safety
+
0.1
%
Modeled Fair Value
$
105.00
Allocation Group
Current Compounder
Modeled Fair Value
$12.435 billion
Allocation Tier
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
An icon graphic of Gouldy the Finch.
#protectYourAssets

Solt DB will launch asset deep dives for all companies in the coverage ecosystem by the end of 2026. These will seamlessly integrate into company-specific financial models, allowing members to determine a company's fair value when specific assets are included or excluded.

Want me to prioritize a specific company or asset? Let me know on Discord or through the contact page.

Last Refined

February 13, 2026
The current model INCLUDES the following assets and assumptions:
The current model is based on operating metrics, including:
  • The model now reflects the acquisition price of $105 per share. The 2026 model basis is presented below, which has a fair value of $64.40 per share.
  • Full-year 2026 revenue of $3.598 billion, representing year-over-year growth of 13.9%.
  • Screening segment revenue of $2.851 billion, representing year-over-year growth of 15.7%.
  • Precision Oncology segment revenue of $746 million, representing year-over-year growth of 7.5%.
  • Operating income of $349 million.
  • Net income of $329 million to $369 million, or earnings per share (EPS) of $1.70 to $1.91.
  • Excludes blood-based screening tools.
The current model EXCLUDES the following assets:

SEC Filings